New Products to Advance Research on Human Pluripotent Stem Cells


STEMCELL Technologies Inc. to Launch TeSR-E8 - a Novel Medium for Human Embryonic and Induced Pluripotent Stem Cells - and New STEMdiff Kits for Differentiation of these cell types

Vancouver (I-Newswire) June 19, 2012 - STEMCELL Technologies Inc. (STEMCELL) announced today its plans to release a series of new products to advance research and translational applications for human pluripotent stem cells.

These novel products, which will be launched at the International Society for Stem Cell Research 2012 Conference in Japan, include:

TeSR™-E8™: a highly defined feeder-free culture medium for human embryonic stem cells (ES cells) and human induced pluripotent stem cells (iPS cells). TeSR-E8 contains only the most essential 8 components required for maintenance of ES cells and iPS cells, providing a simpler medium for the culture of pluripotent stem cells. It is based on the E8 formulation published in Nature Methods (G. Chen et al., Nature Methods 8, 424 (2011)). This lab previously developed the mTeSR™1 and TeSR™2 feeder-free culture media, which were licensed and commercialized by STEMCELL Technologies and are now the most widely-published feeder-free culture media for human pluripotent stem cells. TeSR-E8 can be used with a surface coating of BD Matrigel™ hESC-qualified Matrix or vitronectin, as described in this publication. It will be available for purchase in September 2012 under the license agreement that STEMCELL has with the Wisconsin Alumni Research Foundation (WARF).

STEMdiff™ Definitive Endoderm / Cardiomyocyte / Hematopoietic kits: the STEMdiff product line is significantly expanded with the world’s first complete commercial kits for directed hPSC differentiation to definitive endoderm, cardiomyocyte and hematopoietic lineages. These new kits will be available for purchase in October 2012. STEMdiff products provide robust reagents and protocols to reliably differentiate hPSC to various lineages and are optimized for use with mTeSR™1 and TeSR™2 feeder-free culture media.

“We are delighted to build on our track record for providing high quality cell culture media to stem cell scientists, by introducing new products that work as an integrated system,” said Dr. Allen Eaves, CEO and President of STEMCELL Technologies. “We are excited to give scientists products that are designed to work together and extend from reprogramming through to differentiation.”

By adding TeSR-E8 and the new STEMdiff kits to its portfolio, STEMCELL Technologies continues to provide the most complete, defined system of integrated tools for human pluripotent stem cell research. These high-quality reagents for defined pluripotent cell culture increase experimental reproducibility, eliminate variable biologic elements in the culture media and increase clinical relevance for culture of ES cells and iPS cells.






About STEMCELL Technologies

STEMCELL Technologies Inc. is a leader in the development and marketing of specialty cell culture me   More..dia, cell separation products and ancillary reagents for life science research. Driven by science and enabled by close interactions with global leaders in cell biology and medicine, STEMCELL delivers over 1000 products to research scientists in more than 70 countries worldwide. To learn more about how STEMCELL helps to make research work, visit www.stemcell.com.

About WARF
Since its founding in 1925 to manage a University of Wisconsin–Madison discovery that eventually eliminated the childhood disease rickets, the Wisconsin Alumni Research Foundation has been working with industry to transform university research into products that benefit society. As a private, nonprofit organization, WARF accomplishes its mission of supporting scientific research by patenting and licensing inventions arising from university discoveries. Since making its first grant of $1,200 in 1928, WARF has contributed more than $1 billion to UW–Madison through annual "margin of excellence'' grants and other funding. For more information, visit www.warf.org.Less..

Contact Information

STEMCELL Technologies
Simon Hilcove
Suite 400, 570 W. 7th Ave
Vancouver, BC
V5Z 1B3
Phone : 604-675-7898

Published in:

Science and Research

Published On:

June 19, 2012

Print Release:

Print Release

If you have questions regarding information in this press release contact the company listed above. I-Newswire.com is a press release service and not the author of this press release.The information that is on or available through this site is for informational purposes only and speaks only as of the particular date or dates of that information. As some companies and PR Agencies submit their press releases once per week,month or quarter, make sure to check the official company website for accurate release dates as our site displays the I-Newswire.com press release distribution date only.We do not guarantee the accuracy or completeness of information on or available through this site, and we are not responsible for or omissions in that information or for actions taken in reliance on that information.


Related Releases

F1000Research Aims to Reduce Publication Bias
Open Access life sciences journal, F1000Research, makes a stand to reduce positive bias in the publication record, urging scientists to publish all valid results, including negative and null findings.

Phare Consulting Pushes For Comprehensive Growth In the Security Manufacturing Sector
“Security manufacturing remains an underrated need that has to be sustained, and those who find it necessary may only get it from firms that know exactly what to provide.”

Differentiated & Focused Conference On Polymeric Materials In Medical Devices Undefined. San Francisco, CA, USA, JUNE 26-28, 2013
Learn the latest advances in the field of Polymeric Materials for Medical Applications and meet Medical Device manufacturers such as ABBOTT Vascular, 3-Divisions of JOHNSON & JOHNSON, BOSTON SCIENTIFIC, MEDTRONIC Vascular, St. JUDE MEDICAL, and more

Capital Resource Partners Purchases Gamma Medica’s Pre-Clinical Business to Form New Entity, Trifoil Imaging
Senior Management Team to Remain in Place to Focus on the In-Vivo Molecular Imaging Market

Well Intervention Market Worth $17.48 Billion By 2018
Well Intervention Market will grow from an estimated $9.97 billion in 2013 to $17.48 billion by 2018, with a CAGR of 11.9% from 2013 to 2018.